By Will Boggs, MD NEW YORK (Reuters Health) – Temsirolimus does not improve progression-free survival in metastatic renal cell carcinoma (RCC) compared to standard treatment, according to results…
NEW YORK (Reuters Health) – In patients with potentially resectable colorectal liver metastases, the use of combined PET and CT imaging (PET-CT) identifies those with occult extrahepatic disease…
Recent Videos in Reuters Health • The Doctor’s Channel Newscast Page 213
NEW YORK (Reuters Health) – While minimally invasive radical prostatectomy (MIRP) offers certain advantages over open retropubic radical prostatectomy (RRP), such as a shorter hospital stay, it also…
NEW YORK (Reuters Health) – Tamoxifen therapy has been linked to an increased risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) and now new research suggests…
NEW YORK (Reuters Health) – When adverse events were compared between patients who received single versus multiple coronary stents, there were few complications overall and only a trend…
NEW YORK (Reuters Health) – Stress testing can be safely done in asymptomatic patients with severe aortic stenosis and is useful in predicting adverse cardiac events, including sudden…
NEW YORK (Reuters Health) – In patients with mild renal insufficiency, a single IV bolus of sodium bicarbonate can help prevent contrast-induced nephropathy (CIN) during percutaneous coronary intervention…
NEW YORK (Reuters Health) – The benefit of adding inhaled corticosteroids to long-acting beta-2 agonists for treating chronic obstructive pulmonary disease (COPD) is limited, and furthermore, it’s accompanied…
NEW YORK (Reuters Health) – In patients receiving first-line treatment for metastatic colon cancer, planned complete discontinuation of chemotherapy had a negative impact on duration of disease control…
NEW YORK (Reuters Health) – For patients with chronic obstructive pulmonary disease (COPD), the combination of budesonide/formoterol with tiotropium is more effective than tiotropium alone. The triple therapy…
NEW YORK (Reuters Health) – In a phase III trial in women with HER2/hormone receptor-copositive metastatic breast cancer, the combination of trastuzumab plus anastrozole improved outcomes compared to…
